1. Home
  2. TBPH vs HAFC Comparison

TBPH vs HAFC Comparison

Compare TBPH & HAFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • HAFC
  • Stock Information
  • Founded
  • TBPH 2013
  • HAFC 1982
  • Country
  • TBPH United States
  • HAFC United States
  • Employees
  • TBPH N/A
  • HAFC N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • HAFC Major Banks
  • Sector
  • TBPH Health Care
  • HAFC Finance
  • Exchange
  • TBPH Nasdaq
  • HAFC Nasdaq
  • Market Cap
  • TBPH 699.0M
  • HAFC 712.5M
  • IPO Year
  • TBPH N/A
  • HAFC 1996
  • Fundamental
  • Price
  • TBPH $13.95
  • HAFC $24.94
  • Analyst Decision
  • TBPH Strong Buy
  • HAFC Buy
  • Analyst Count
  • TBPH 3
  • HAFC 6
  • Target Price
  • TBPH $21.33
  • HAFC $26.00
  • AVG Volume (30 Days)
  • TBPH 602.7K
  • HAFC 163.1K
  • Earning Date
  • TBPH 08-12-2025
  • HAFC 10-21-2025
  • Dividend Yield
  • TBPH N/A
  • HAFC 4.33%
  • EPS Growth
  • TBPH N/A
  • HAFC N/A
  • EPS
  • TBPH 0.26
  • HAFC 2.16
  • Revenue
  • TBPH $77,205,000.00
  • HAFC $233,739,000.00
  • Revenue This Year
  • TBPH $78.36
  • HAFC $17.13
  • Revenue Next Year
  • TBPH N/A
  • HAFC $7.95
  • P/E Ratio
  • TBPH $54.52
  • HAFC $11.55
  • Revenue Growth
  • TBPH 24.49
  • HAFC N/A
  • 52 Week Low
  • TBPH $7.88
  • HAFC $17.90
  • 52 Week High
  • TBPH $14.55
  • HAFC $27.59
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 71.41
  • HAFC 56.39
  • Support Level
  • TBPH $13.66
  • HAFC $24.58
  • Resistance Level
  • TBPH $14.55
  • HAFC $25.64
  • Average True Range (ATR)
  • TBPH 0.46
  • HAFC 0.54
  • MACD
  • TBPH -0.02
  • HAFC 0.09
  • Stochastic Oscillator
  • TBPH 56.20
  • HAFC 67.69

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About HAFC Hanmi Financial Corporation

Hanmi Financial Corp is a Los Angeles-based bank that caters to Korean-Americans and other multi-ethnic communities across California, Colorado, Georgia, Illinois, New Jersey, New York, Texas, Virginia, and Washington. The bank mainly focuses on small businesses and commercial and real estate loans. It also offers a variety of international finance and trade services and products, including letters of credit, import financing, and export financing. The Bank's revenues are derived from interest and fees on loans, interest, and dividends on the securities portfolio, service charges on deposit accounts, and sales of SBA loans.

Share on Social Networks: